Clinical trial · Interventional
Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation
Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation (CHACRY-1501)
NCT02871167CI-TRIAL-00105852CHACRYactive not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to perform a French multicenter prospective interventional study in order to assess the feasibility and safety of ovarian hyperstimulation for oocyte / embryo cryopreservation in young women with breast cancer. The oncologic and reproductive benefit / risk ratio will be investigated in the oncology and reproductive area.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Controlled ovarian hyperstimulation (COH) | Procedure | — | UNRESOLVED |
| Oocyte/embryo freezing | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Oocyte/embryo cryopreservation
- description
- 1. Controlled ovarian hyperstimulation (COH) 2. Oocyte/embryo freezing
- interventionNames
- Procedure: Controlled ovarian hyperstimulation (COH)
- Procedure: Oocyte/embryo freezing
Primary outcomes (1)
- measure
- Quality of oocytes: total number of oocytes preserved
- timeFrame
- after oocyte retrieval (35-36 hours after triptorelin injection)
- description
- The distribution of the total number of oocytes preserved will be summarized by the mean (standard error) and median (range) and presented with a 95% confidence interval.
Secondary outcomes (8)
- measure
- Quality of embryos: total number of embryos preserved
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 38 Years
Show eligibility criteria text
Inclusion Criteria: * Women with histologically proven breast cancer * Aged 18 to 38 years old * Planned adjuvant chemotherapy * No prior chemotherapy * Affiliated to a public health insurance program * Informed consent signed by the patient Exclusion Criteria: * Metastatic breast cancer * Planned neo-adjuvant chemotherapy * Hysterectomy * Exclusive adjuvant hormonotherapy * Positive serology for syphilis, hepatitis B or C, or VIH * Contraindication related to use of r-FSH * Pregnant or breastfeeding patients
References
Publications (0)
Data not yet available
No reference posted for this study.